📰 Mabwell Bioscience News
Mabwell Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mabwell Bioscience. Real-time updates on events, politics, business and more.
January 24, 2023
/PRNewswire/ -- The "China Anti-Rheumatic Drug Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.coms offering. China...
January 20, 2023
Dublin, Jan. 20, 2023 (GLOBE NEWSWIRE) -- The "China Anti-Rheumatic Drug Market - Forecasts from 2022 to 2027" report has been added to ...
December 20, 2022
/PRNewswire/ -- Mabwell Bioscience (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, today announced the company...
November 22, 2022
Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Approval of Supplemental Application for Additional Indications of Adalimumab Injection
November 22, 2022
SHANGHAI, China, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading...
November 22, 2022
SHANGHAI, China, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated
March 10, 2022
Shanghai Junshi Biosciences Co. Ltd. and Mabwell Bioscience Co. Ltd. announced that the jointly developed adalimumab biosimilar injection (Junmaikang ®) was officially approved by...
March 9, 2022
Shanghai Junshi Biosciences Co. Ltd. and Mabwell Bioscience Co. Ltd. announced that the jointly developed adalimumab biosimilar injection (Junmaikang ®) was officially approved by the...